Compile Data Set for Download or QSAR
Report error Found 544 Enz. Inhib. hit(s) with all data for entry = 10247
TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522443(9-(4-(3,5-dimethyl-1H- | US11161848, Compound I-21...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522444(US11161848, Compound I-2 | 2-(2-isopropylpyridin-3...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM324802(9-(4-(1H-pyrazol-1- | US10189841, Compound I-8 | U...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM324805(9-(4-(1H-pyrazol-1- | US10189841, Compound I-11 | ...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522468(US11161848, Compound I-26 | 9-(4-(1-methyl-4-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522472(US11161848, Compound I-30 | 2-(2-cyclopropylpyridi...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522473(US11161848, Compound I-31 | 2-(2-(difluoromethyl)p...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522475(US11161848, Compound I-33 | 2-(2-cyclopropylpyridi...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522476(US11161848, Compound I-34 | 9-(4-(1-methyl-4-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522477(US11161848, Compound I-35 | 2-(2-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522479(US11161848, Compound I-37 | 9-(4-(1-methyl-4-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522480(US11161848, Compound I-38 | 2-(2-acetylphenyl)-9-(...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522482(US11161848, Compound I-40 | 2-(2-isopropylpyridin-...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522484(US11161848, Compound I-42 | 9-(4-(5-methyl-3-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522486(US11161848, Compound I-44 | 2-(1-methyl-1H-indazol...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522487(US11161848, Compound I-45 | 2-(1-methyl-1H-indol-7...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM324842(2-(2- | US10189841, Compound I-48 | US10399980, Co...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522491(US11161848, Compound I-49 | 7-methyl-9-(4-(1-methy...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM324844(7-methyl-9-(4-(1-methyl-4- | US10189841, Compound ...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522493(US11161848, Compound I-51 | 2-(2-isopropylpyridin-...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522494(US11161848, Compound I-52 | 9-(4-(3-chloro-5-methy...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522495(US11161848, Compound I-53 | 9-(4-(5-chloro-3-methy...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522497(US11161848, Compound I-55 | (R)-2-(2-(1-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522498(US11161848, Compound I-56 | (S)-2-(2-(1-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522500(US11161848, Compound I-58 | 9-(4-(3-(difluoromethy...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522502(US11161848, Compound I-60 | 2-(2-isopropylpyridin-...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM324857(2-(2-isopropylphenyl)-7- | US10189841, Compound I-...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM324859(2-(3-fluoro-2- | US10189841, Compound I-65 | US103...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522509(US11161848, Compound I-67 | 2-(5-fluoro-2-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM324863(2-(5-fluoro-2- | US10189841, Compound I-69 | US103...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM417177(2-(2-cyclopropylphenyl)-7-methyl-9-(4-(1-methyl-4-...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM324865(2-(2-cyclopropylpyridin-3-yl)- | US10189841, Compo...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM324867(2-(6-methoxy-2- | US10189841, Compound I-73 | US10...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522518(US11161848, Compound I-76 | 9-(4-(1-cyclopropyl-4-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522519(US11161848, Compound I-77 | 2-(2-isopropylpyridin-...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522520(US11161848, Compound I-78 | 2-(2-isopropylpyridin-...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522521(US11161848, Compound I-79 | (R)-2-(2-isopropylpyri...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522522(US11161848, Compound I-80 | (S)-2-(2-isopropylpyri...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522523(US11161848, Compound I-81 | 2-(2-isopropylpyridin-...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522524(US11161848, Compound I-82 | 9-(3,5-difluoro-4-(1-m...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522525(US11161848, Compound I-83 | 9-(3-fluoro-4-(1-methy...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522526(US11161848, Compound I-84 | 9-(2-fluoro-4-(1-methy...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522532(US11161848, Compound I-90 | 2-(2-(dimethylamino)ph...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522533(US11161848, Compound I-91 | 9-(4-(1H-pyrazol-1-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522536(US11161848, Compound I-94 | 9-(4-(1H-pyrazol-1-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522537(US11161848, Compound I-95 | 9-(4-(1H-pyrazol-1-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522538(US11161848, Compound I-96 | 9-(4-(1H-pyrazol-1-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522540(US11161848, Compound I-98 | 2-(2-cyclopropylphenyl...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM522541(US11161848, Compound I-99 | ethyl 1-(4-((2-(2-)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 1(Human)
Forma Therapeutics

US Patent
LigandPNGBDBM324894(7-cyclopropyl-2-(2- | US10189841, Compound I-100 |...)
Affinity DataIC50: 50nMAssay Description:The HTS assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 544 total ) | Next | Last >>
Jump to: